Comparison of in vivo efficacy of BCX-1777 and cyclosporin in xenogeneic graft-vs.-host disease: The role of dGTP in antiproliferative action of BCX-1777

International Immunopharmacology

Volumn 2, Issue 7, 2002, Pages 913-923

  Bantia, Shanta ^a   Miller, Patrick J ^a   Parker, Cynthia D ^a   Ananth, Sandya L ^a   Horn, LaShun L ^a   Babu, Yarlagadda S ^a   Sandhu, Jasbir S ^b  

^a BIOCRYST PHARMACEUTICALS INC   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Graft vs. host disease; Immunomodulators; In vivo animal models; T lymphocytes

Indexed keywords

CYCLOSPORIN; DEOXYADENOSINE TRIPHOSPHATE; DEOXYCYTIDINE TRIPHOSPHATE; DEOXYGUANOSINE; DEOXYGUANOSINE TRIPHOSPHATE; DEOXYRIBONUCLEOTIDE; DNA FRAGMENT; IMMUCILLIN H; PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR; THYMIDINE TRIPHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MODEL; DISEASE SEVERITY; DNA DAMAGE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SCID MOUSE; T LYMPHOCYTE; XENOGRAFT;

ANIMALS; CYCLOSPORINE; DEOXYGUANINE NUCLEOTIDES; DOGS; DRUG THERAPY, COMBINATION; GRAFT VS HOST DISEASE; GROWTH INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES; MACACA FASCICULARIS; MICE; MICE, INBRED BALB C; MICE, SCID; PYRIMIDINONES; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; SURVIVAL RATE; TRANSPLANTATION, HETEROLOGOUS;

EID: 0036317944     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(02)00034-6     Document Type: Article

References (23)

1. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity
2. Abnormal purine metabolism and purine overproduction in a patient deficient of purine nucleoside phosphorylase
3. An abnormal form of a purine nucleoside phosphorylase in a family with a child with severe defective T-cell and normal B-cell immunity
4. Purine nucleoside phosphorylase deficiency
5. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H) - A novel potent and orally active immunosuppressive agent
6. In vivo and in vitro pharmacological activity of the purine nucleoside phosphorylase inhibitor BCX-34: The role of GTP and dGTP
7. Purine nucleoside phosphorylase inhibitors: Biochemical and pharmacological studies with 9-benzyl-9-deazaguanine and related compounds
8. One-third-the sites transition-state inhibitors for purine nucleoside phosphorylase
9. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes
10. A human model of xenogeneic graft-versus-host disease in SCID mice engrafted with human peripheral blood lymphocytes
11. Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells
12. Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers
13. Transfer of a functional human immune system to mice with severe combined immunodeficiency
14. Deoxycytidine kinase from calf thymus: Substrate and inhibitor specificity
15. Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine: Selective toxicity for T-lymphocytes
16. Allosteric regulation of calf thymus ribonucleoside diphosphate reductase
17. DNTP pools imbalance as a signal to initiate apoptosis
18. Imbalance of deoxyribonucleoside triphosphates, DNA double-strand breaks, and cell death caused by 2-chlorodeoxyadenosine in mouse FM3A cells
19. Regulation of the salvage pathway of deoxynucleotides synthesis in apoptosis induced by growth factor deprivation
20. Overview of transplantation immunology and the pharmacotherapy of adult solid organ transplant recipients: Focus on immunosuppression
21. Therapeutic strategies in autoimmune disease: Cyclosporin A as a model agent
22. Efficacy of cyclosporin A (CyA) in psoriasis: An overview of dose/response, indications, contraindications and side effects
23. New developments in the prophylaxis and treatment of graft versus host disease